New details have emerged about how Alzheimer’s disease affects the brain. Researchers led by the Allen Institute for Brain Science in Seattle and University of Washington Medicine have ...

Kayden Muller Janssen and Adrianna Siena on the red carpet at the Alzheimer’s Association 7th Annual Dance Party to End ALZ: Halloween Edition on Sunday, October 27, 2024, at AVALON Hollywood, in Los ...

November is National Family Caregivers Month which highlights the emotional and practical demands for family members forced into those roles.

Hallucinations are a fairly common symptom in the advanced stages of Alzheimer’s disease. Treatment options like medications or therapy can help reduce their frequency and effect. Alzheimer’s ...

Alzheimer’s disease may cause cognitive complications like severe memory loss, mental health complications like depression, and physical complications like reduced mobility. Alzheimer’s ...

Each year, Baylor Medicine's Alzheimer Disease and Memory Disorders Center manages more than 3,000 patient visits. People come to our center for diagnosis of their memory problems, treatment and ...

Pascal Geldsetzer believes in open access, in disseminating science as quickly as it happens. Even so, last summer, as he uploaded the surprising results of his latest study to the MedRxiv ...

Donanemab, also known as Kisunla, has recently been licensed as a treatment for early-stage Alzheimer’s disease in the UK. However, donanemab has not been recommended for use in the NHS. Here's what ...

Semaglutide medications — such as Ozempic, the popular diabetes drug — have been linked to a reduced risk of Alzheimer’s disease for certain groups. A new study, which was led by researchers ...

During an annual checkup, the patient says: “Doc, I saw a commercial about a blood test that can tell if I’ll develop Alzheimer’s. I watched my mother go through it. I want to get tested.” ...

The only approved treatments for Alzheimer’s disease are medications with limited effectiveness and a risk of severe, sometimes deadly, side effects. That’s why scientists search for therapies ...

Mizuho said U.S. sales of the company's leqembi Alzheimer's disease treatment of $39 million were below the consensus for $55 million, and that overall product revenue was about $80 million below ...